Rational use of biological response modifiers in hematological malignancies—A review of treatment with interferon, cytotoxic cells and antibodies
- 31 December 1989
- journal article
- review article
- Published by Elsevier in Leukemia Research
- Vol. 13 (12) , 1039-1046
- https://doi.org/10.1016/0145-2126(89)90148-3
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Lymphokine Activated Killer (LAK) Cells in Antibody Dependent Cellular Cytotoxicity (ADCC) Using MAb 17-1A: A Combination of Potential Usefulness in Tumor TherapyHybridoma, 1989
- Immunotherapy of cancer using interleukin 2: current status and future prospectsImmunology Today, 1988
- REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1HThe Lancet, 1988
- Effect of Human Blood Mononuclear Cell Populations in Antibody Dependent Cellular Cytotoxicity (ADCC) Using Two Murine (CO 17-1A and Br55-2) and One Chimeric (17-1A) Monoclonal Antibodies Against a Human Colorectal Carcinoma Cell Line (SW948)Hybridoma, 1988
- Treatment of multiple myeloma with natural α‐interferonHematological Oncology, 1988
- Interferon therapy for lymphoproliferative disordersPublished by Springer Nature ,1988
- Analysis of the idiotypic network in tumor immunity.The Journal of Immunology, 1987
- Sequences and repertoire of the human T cell receptor α and β chain variable region genes in thymocytesEuropean Journal of Immunology, 1987
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975